Nitazoxanide is an orally active nitrothiazoly-salicylamide broad-spectrum antiparasitic and antiviral prodrug that is converted rapidly to the active metabolites tizoxanide and tizoxanide conjugates, these metabolites appear to be safer and free of mutagenic effects. Nitazoxanide is also known to potentiate interferon alfa and interferon beta production. When nitazoxanide was given as 600 mg twice daily for 5 days, it’s proved to reduce of the duration of symptoms in patients with acute uncomplicated influenza and this dose regimen might be reasonably considered to be used combined with azithromycin in a suggested new COVID-19 protocol aiming to test their integrated potential to decrease SARS CoV-2 morbidity and mortality.